Vertex wagers $70M on Kymera and its new fascination with protein degradation
One of Vertex’s key promises to investors and patients has been that it will deploy its success in cystic fibrosis — which finally turned the 30-year-old biotech into a profitable business three years ago — to fund more R&D projects with innovative technologies. It has propelled them to dive into gene editing, team up with CRISPR Therapeutics to test what could be a pioneering treatment for sickle cell disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.